The Oral Calcilytic Encaleret Decreased the Fractional Excretion of Calcium in Individuals with Post-surgical Hypoparathyroidism: Preliminary Findings from an Ongoing Open-label Phase 2 Study

被引：0
|
作者：
Gafni, Rachel I. [1 ]
Roszko, Kelly L. [1 ]
Li, Xiaobai [2 ]
Ferguson, Elizabeth A. [1 ]
Moore, Casey A. [1 ]
Pozo, Karen A. [1 ]
Ampuero, Kimberly T. [1 ]
Meadows, Rita E. J. [1 ]
Sridhar, Ananth V. [3 ]
Mathew, Arun S. [3 ]
Roberts, Mary Scott [3 ]
Adler, Scott H. [3 ]
Nemeth, Edward F. [4 ]
Collins, Michael T. [1 ]
机构：
[1] Nat Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA
[2] NIH, Biostat & Clin Epidemiol, Clin Ctr, Bethesda, MD USA
[3] Calcilytix Therapeut Inc, San Francisco, CA USA
[4] MetisMedica, Montreal, PQ, Canada
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-LB 591
引用
收藏
页码：360 / 361
页数：2
相关论文
共 50 条
  • [31] Preliminary results from HERKULES-1: a phase 1b/2, open-label, multi-center study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors
    Wang, J.
    Johnson, M.
    Barve, M.
    Pelster, M.
    Chen, X.
    Li, Z.
    Gordon, J.
    Reiss, M.
    Pai, S.
    Falchook, G.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S80 - S81
  • [32] Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China
    Liang, Xieer
    Hou, Jinlin
    Guan, Yujuan
    Zhang, Zhanqing
    Xie, Qing
    Jia, Jidong
    Sheng, Jifang
    Ning, Qin
    Yang, Wang
    Mozaffarian, Afsaneh
    Unchwaniwala, Nuruddin
    Liu, Jieming
    Zomorodi, Katie
    Stamm, Luisa M.
    Knox, Steven J.
    Anderson, Michele
    Kitrinos, Kathryn M.
    Wang, Grace
    Chen, Yu
    Niu, Junqi
    JOURNAL OF HEPATOLOGY, 2023, 78 : S1153 - S1154
  • [33] Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study
    Wang, Jiabei
    Peng, Tao
    Liu, Chang
    Zhang, Ling
    Zhu, Guangzhi
    Zhang, Xiaogang
    Wang, Xiaoqian
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] ZETOMIPZOMIB IS ASSOCIATED WITH CLINICALLY MEANINGFUL REDUCTION OF PROTEINURIA IN LN CLASS III/IV WITH OR WITHOUT CLASS V: POST-HOC ANALYSIS FROM THE OPEN-LABEL MISSION PHASE 2 STUDY
    Parikh, Samir V.
    Saxena, Amit
    Leff, Richard
    Li, Elaine
    Park, Eunmi
    Henig, Noreen R.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S96 - S96
  • [35] Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).
    Fakih, Marwan
    Segal, Neil Howard
    Schlechter, Benjamin L.
    Andre, Thierry
    Pietrantonio, Filippo
    Johnson, Benny
    Vasilyev, Alexander
    Krishnamurthi, Smitha S.
    Siena, Salvatore
    Messersmith, Wells A.
    Silva, Virgilio
    Paulson, Andrew Scott
    Elez, Elena
    Eng, Cathy
    Tejpar, Sabine
    Ducreux, Michel Pierre
    Wu, Wei
    Grossman, Joseph Elan
    Van Cutsem, Eric
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 23 - 23
  • [36] XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy
    French, Jacqueline
    Porter, Roger
    Perucca, Emilio
    Brodie, Martin
    Rogawski, Michael
    Harden, Cynthia
    Qian, Jenny
    Luzon-Rosenblut, Constanza
    Kenney, Christopher
    Beatch, Gregory
    NEUROLOGY, 2023, 100 (17)
  • [37] XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy
    French, J.
    Porter, R.
    Perucca, E.
    Brodie, M.
    Rogawski, M. A.
    Harden, C.
    Qian, J.
    Luzon-Rosenblut, C.
    Kenney, C.
    Beatch, G. N.
    EPILEPSIA, 2023, 64 : 275 - 276
  • [38] Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors
    Kefford, Richard
    Miller, Wilson H.
    Tan, Daniel Shao-Weng
    Sullivan, Ryan J.
    Long, Georgina
    Dienstmann, Rodrigo
    Tai, Wai Meng David
    Flaherty, Keith
    Stutvoet, Simone
    Schumacher, Karl Maria
    Wandel, Simon
    De Parseval, Laure A.
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Preliminary clinical safety and efficacy results from an open-label phase II study of STA-5326, an oral IL-12/IL-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis
    Gottlieb, A
    Cather, J
    Hamilton, T
    Hudson, C
    Krell, J
    Baker, D
    Sherman, M
    Jacobson, E
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (01)
  • [40] Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
    Durrant, Simon T.
    Nagler, Arnon
    Guglielmelli, Paola
    Lavie, David
    le Coutre, Philipp
    Gisslinger, Heinz
    Chuah, Charles
    Maffioli, Margherita
    Bharathy, Savita
    Dong, Tuochuan
    Wroclawska, Monika
    Martinez Lopez, Joaquin
    HAEMATOLOGICA, 2019, 104 (12) : E551 - E554
12345